Brief: Bio-Rad Q3 Adjusted EPS USD 2.33 Vs. IBES Estimate USD 2.78
26/10/2023 21:15
Oct 26 (Reuters) - Bio-Rad Q3 EBIT margin 14.4%. * Q3 net income USD 106.3 million * Q3 gross margin 53.1% * Q3 EPS USD 3.64 * Q3 sales USD 632.1 million vs. IBES estimate USD 689.6 million
Recent news on Bio-Rad Laboratories
See all newsBio-Rad Laboratories, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Bio-Rad Laboratories On July 31, Initiated Restructuring Plan - SEC Filing
Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth
Brief: Bio-Rad Q2 Net Income USD 371.4 Million
Activist investors make bigger push for campaigns in H1, seek more M&A